EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie

Multicenter Pivotal Study of the Alterra Adaptive Prestent for the Treatment of Pulmonary Regurgitation

V Vivian Dimas, Vasilis Babaliaros, Dennis Kim, D Scott Lim, Gareth Morgan, Thomas K Jones, Aimee K Armstrong, Darren Berman, Jamil Aboulhosn, Vaikom S Mahadevan, Matthew J Gillespie, David Balzer und 8 weitere

JACC: Cardiovascular Interventions · 2024

DOI: 10.1016/j.jcin.2024.07.036 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2024. Verfasst von V Vivian Dimas und 19 weiteren Autor:innen. Beteiligte Einrichtung: Medical City Children's Hospital, Dallas, Texas, USA. Electronic address: vivian.dimas@hcahealthcare.com. Hauptthemen laut MEDLINE: Pulmonary Valve Insufficiency, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Pulmonary Valve. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Edwards Lifesciences Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: A dilated native right ventricular outflow tract (RVOT) presents unique challenges for transcatheter management using balloon-expandable valves. The Alterra Adaptive Prestent was designed to expand transcatheter therapy to treat patients with dilated RVOTs. OBJECTIVES: The aim of this study was to report 2-year outcomes of the main cohort of the ALTERRA (Multicenter Study of Congenital Pulmonic Valve Dysfunction Studying the SAPIEN 3 THV With the Alterra Adaptive Prestent) pivotal trial using the prestent with transcatheter pulmonary valve replacement. METHODS: The prestent device used with the 29 mm SAPIEN 3 transcatheter heart valve (THV) was evaluated for the management of patients with moderate or greater pulmonary valve regurgitation (PR). The primary endpoint was THV dysfunction at 6 months, defined as a nonhierarchical composite of RVOT/pulmonary valve reintervention, moderate or greater total PR on transthoracic echocardiography, and mean RVOT/pulmonary valve gradient 35 mm Hg or greater on transthoracic echocardiography. The primary endpoint and outcomes through 2 years are presented in this analysis. RESULTS: Of 97 patients screened, 60 underwent prestent and THV implantation. There was 1 staged procedure. No patients had THV dysfunction at 6 months. At 2 years, the majority of patients (92.5%) had mild or less PR, with no reports of coronary compression, stent fractures warranting reintervention, or endocarditis. Of the 21 patients (34.4%) who experienced early (days 0-1) arrhythmias, 12 had episodes of nonsustained ventricular tachycardia that resolved with medication. One patient underwent reintervention secondary to an iatrogenic RVOT obstruction; there were no deaths or explantations through 2 years. CONCLUSIONS: The Alterra prestent in combination with the SAPIEN 3 THV has excellent outcomes at 2 years, with no significant valve dysfunction in the main pivotal cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Valve InsufficiencyHeart Valve ProsthesisHeart Valve Prosthesis ImplantationPulmonary ValveCardiac CatheterizationProsthesis DesignRecovery of FunctionHumansTreatment OutcomeMaleFemaleTime FactorsAdultUnited StatesYoung AdultHemodynamicsAdolescentProspective StudiesMiddle AgedBalloon ValvuloplastyRisk FactorsEurope

Stichwörter der Autor:innen

Alterra Adaptive PrestentSAPIEN 3 THVpulmonary regurgitationright ventricular outflow tract/pulmonary valve dysfunctiontranscatheter pulmonary valve replacement

Autor:innen und Institutionen

  • Medical City Children's Hospital, Dallas, Texas, USA. Electronic address: vivian.dimas@hcahealthcare.com.
  • Emory University, Atlanta, Georgia, USA.
  • Emory University, Atlanta, Georgia, USA; Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • University of Virginia, Charlottesville, Virginia, USA.
  • Children's Hospital of Colorado, University of Colorado, Denver, Colorado, USA.
  • Seattle Children's Hospital, Seattle, Washington, USA.

Förderung

  • Edwards Lifesciences Corporation

Zitieren

APA

Dimas, V. V., Babaliaros, V., Kim, D., Lim, D. S., Morgan, G., Jones, T. K., Armstrong, A. K., Berman, D., Aboulhosn, J., Mahadevan, V. S., Gillespie, M. J., Balzer, D., Zellers, T., Yu, X., Shirali, G., Parthiban, A., Leipsic, J., Blanke, P., Zahn, E., & Shahanavaz, S. (2024). Multicenter Pivotal Study of the Alterra Adaptive Prestent for the Treatment of Pulmonary Regurgitation. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2024.07.036

Vancouver

Dimas VV, Babaliaros V, Kim D, Lim DS, Morgan G, Jones TK, et al. Multicenter Pivotal Study of the Alterra Adaptive Prestent for the Treatment of Pulmonary Regurgitation. JACC: Cardiovascular Interventions. 2024. doi:10.1016/j.jcin.2024.07.036

BibTeX
@article{Dimas2024,
  author = {Dimas, V Vivian and Babaliaros, Vasilis and Kim, Dennis and Lim, D Scott and Morgan, Gareth and Jones, Thomas K and Armstrong, Aimee K and Berman, Darren and Aboulhosn, Jamil and Mahadevan, Vaikom S and Gillespie, Matthew J and Balzer, David and Zellers, Thomas and Yu, Xiao and Shirali, Girish and Parthiban, Anitha and Leipsic, Jonathan and Blanke, Philipp and Zahn, Evan and Shahanavaz, Shabana},
  title = {Multicenter Pivotal Study of the Alterra Adaptive Prestent for the Treatment of Pulmonary Regurgitation},
  journal = {JACC: Cardiovascular Interventions},
  year = {2024},
  doi = {10.1016/j.jcin.2024.07.036}
}
Kostenlos starten →